Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huage granules for prevention of postoperative recurrence and metastasis in esophageal squamous cell carcinoma
ChiCTR2400086556Phase 3Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jul 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Huage granules with Placebo (2 arms). Primary endpoint: 2-year disease-free survival rate. Started Jul 2024; status: recruiting.
02
Drugs
Huage granules
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2400086556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086556.